enGene’s detalimogene shows 71% response rate in bladder cancer

enGene’s non-viral lead investigational product detalimogene is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guerin, or BCG, -unresponsive, non-muscle invasive bladder cancer – NMIBC – with carcinoma in situ – Cis -. The company announced preliminary data from 21 patients assessed at three months, including 17 patients who were also assessed at six months, in the ongoing pivotal cohort of the LEGEND study. Complete Response rate at any time was 71%, the CR rate at three months was 67% and the CR rate at six months was 47%. Detalimogene was generally well-tolerated by patients and no patients discontinued due to treatment-related adverse events.